|DB00206||Reserpine||Foe the treatment of hypertension|
|DB00216||Eletriptan||For the acute treatment of migraine with or without aura in adults.|
|DB00305||Mitomycin||For treatment of malignant neoplasm of lip, oral cavity, pharynx, digestive organs, peritoneum, female breast, and urinary bladder. Also used as an adjunct to ab externo glaucoma surgery.|
|DB00309||Vindesine||For the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia and acute panmyelosis|
|DB00315||Zolmitriptan||For the acute treatment of adult migraine with or without auras.|
|DB00328||Indometacin||Oral indometacin is indicated for symptomatic management of moderate to severe rheumatoid arthritis including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.[A177871,L6778]
Intravenous indometacin is indicated to induce closure of a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1750 g when after 48 hours usual medical management (e.g., fluid restriction, diuretics, digitalis, respiratory support, etc.) is ineffective.[F4600]|
Vinorelbine tartrate is indicated for adults in the treatment of advanced non-small cell lung cancer (NSCLC), as a single therapy or in combination with other chemotherapeutic drugs [L1998].
Used in relapsed or refractory Hodgkin lymphoma, in combination with other chemotherapy agents [L2011].
For the treatment of desmoid tumor or aggressive fibromatosis, in combination with methotrexate [L2011].
For the treatment of recurrent or metastatic squamous cell head and neck cancer [L2011].
For the treatment of recurrent ovarian cancer [L2011].
For the treatment of metastatic breast cancer, in patients previously treated with anthracyline and/or taxane therapy [L2011].
For the treatment of HER2-positive, trastuzumab-resistant, advanced breast cancer in patients previously treated with a taxane, in combination with trastuzumab and everolimus [L2011].
|DB00541||Vincristine||Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL). |
|DB00570||Vinblastine||For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.|
|DB00669||Sumatriptan||For the treatment of migraine attacks with or without aura.|
|DB00705||Delavirdine||For the treatment of HIV-1 infection in combination with appropriate antiretroviral agents when therapy is warranted|
|DB00749||Etodolac||For acute and long-term management of signs and symptoms of osteoarthritis and rheumatoid arthritis, as well as for the management of pain.|
|DB00790||Perindopril||For the treatment of mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease. |
|DB00808||Indapamide||For the treatment of hypertension, alone or in combination with other antihypertensive drugs, as well as for the treatment of salt and fluid retention associated with congestive heart failure or edema from pregnancy (appropriate only in the management of edema of pathologic origin during pregnancy when clearly needed). Also used for the management of edema as a result of various causes.|
|DB00820||Tadalafil||Used for the treatment of erectile dysfunction.|
|DB00821||Carprofen||For use as a pain reliever in the treatment of joint pain and post-surgical pain.|
|DB00904||Ondansetron||In the adult patient population:
i) orally administered ondansetron tablets and orally disintegrating tablets (ODT) are indicated for:
- the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including high dose (ie. greater than or equal to 50 mg/m2) cisplatin therapy, and radiotherapy, and
- the prevention and treatment of postoperative nausea and vomiting
ii) intravenously administered ondansetron injection formulations are indicated for:
- the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including high dose (ie. greater than or equal to 50 mg/m2) cisplatin therapy, and
- the prevention and treatment of postoperative nausea and vomiting
In the pediatric (4-18 years of age) patient population:
i) ondansetron was effective and well tolerated when given to children 4-12 years of age for the treatment of post-chemotherapy induced nausea and vomiting,
ii) ondansetron tablets, ondansetron ODT, ondansetron injection are not indicated for the treatment of children 3 years of age or younger,
iii) ondansetron tablets, ondansetron ODT, ondansetron injection are not indicated for use in any age group of the pediatric population for the treatment of post-radiotherapy induced nausea and vomiting, and
iV) ondansetron tablets, ondansetron ODT, ondansetron injection are not indicated for use in any age group of the pediatric population for the treatment of postoperative nausea and vomiting
In the geriatric (>65 years of age) patient population:
i) efficacy and tolerance of ondansetron were similar to that observed in younger adults for the treatment of post-chemotherapy and radiotherapy-induced nausea and vomiting, and
ii) clinical experience in the use of ondansetron in the prevention and treatment of postoperative nausea and vomiting is limited and is not indicated for use in the geriatric patient population |
|DB00918||Almotriptan||For the treatment of acute migraine headache in adults|
|DB00952||Naratriptan||For the acute treatment of migraine attacks with or without aura in adults.|
|DB00953||Rizatriptan||For treatment of acute migraine attacks with or without aura.|
|DB00969||Alosetron||Only for the treatment of symptoms of severe diarrhea-predominant irritable bowel syndrome (IBS) in women with chronic symptoms (generally lasting greater than 6 months) who does not present with anatomic or biochemical GI abnormalities and have not responded to conventional therapy.|
|DB00981||Physostigmine||For the treatment of glaucoma, and in the treatment of severe anticholinergic toxicity.|
|DB00998||Frovatriptan||For the acute treatment of migraine attacks with or without aura in adults.|
|DB01065||Melatonin||Used orally for jet lag, insomnia, shift-work disorder, circadian rhythm disorders in the blind (evidence for efficacy), and benzodiazepine and nicotine withdrawal. Evidence indicates that melatonin is likely effective for treating circadian rhythm sleep disorders in blind children and adults. It has received FDA orphan drug status as an oral medication for this use. A number of studies have shown that melatonin may be effective for treating sleep-wake cycle disturbances in children and adolescents with mental retardation, autism, and other central nervous system disorders. It appears to decrease the time to fall asleep in children with developmental disabilities, such as cerebral palsy, autism, and mental retardation. It may also improve secondary insomnia associated with various sleep-wake cycle disturbances. Other possible uses for which there is some evidence for include: benzodiazepine withdrawal, cluster headache, delayed sleep phase syndrome (DSPS), primary insomnia, jet lag, nicotine withdrawal, preoperative anxiety and sedation, prostate cancer, solid tumors (when combined with IL-2 therapy in certain cancers), sunburn prevention (topical use), tardive dyskinesia, thrombocytopenia associated with cancer, chemotherapy and other disorders. |
|DB01089||Deserpidine||For the treatment of hypertension.|
|DB01136||Carvedilol||For the treatment of mild or moderate (NYHA class II or III) heart failure of ischemic or cardiomyopathic origin.|
|DB01180||Rescinnamine||For the treatment of hypertension.|
|DB01392||Yohimbine||Indicated as a sympatholytic and mydriatic. Impotence has been successfully treated with yohimbine in male patients with vascular or diabetic origins and psychogenic origins.|
|DB01426||Ajmaline||For use as an antiarrhythmic agent.|
|DB01488||Dimethyltryptamine||Some people use this compound as a psychedelic inducing agent.|
|DB01546||Etryptamine||Developed in the 1960's for use as an antidepressant before market withdrawal in 1962.
|DB01618||Molindone||Molindone is used for the management of the manifestations of psychotic disorders.|
|DB04867||Lintitript||For the treatment of pancreatic cancer and appetite disorders.|
|DB04877||Voacamine||For the treatment of malaria. Also under investigation for the modulation of multidrug resistance in cancer cells.|
|DB04882||Edotecarin||Clinical studies with edotecarin have shown activity in subjects with colorectal cancer, esophageal cancer and other solid tumors.|
|DB04885||Cilansetron||For the treatment of symptoms associated with irritable bowel syndrome.|
|DB04892||Phenserine||For the treatment of Alzheimer's disease (AD).|
|DB05168||Vintafolide||Investigated for use/treatment in solid tumors.|
|DB05403||CEP-1347||Investigated for use/treatment in asthma and parkinson's disease.|
|DB06362||Becatecarin||Investigated for use/treatment in cancer/tumors (unspecified), liver cancer, gastric cancer, and leukemia (unspecified).|
|DB06469||Lestaurtinib||Investigated for use/treatment in pancreatic cancer, prostate cancer, and leukemia (myeloid).|
|DB06478||Porfiromycin||Investigated for use/treatment in head and neck cancer.|
|DB06595||Midostaurin||Investigated for use/treatment in adult patients with high-risk acute myeloid leukemia (AML) who are FLT3 mutation-positive, agressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL). |
|DB06684||Vilazodone||Vilazodone is approved for treatment of major depressive disorder[Label,A38477,A177622].|
|DB09012||Carbazochrome||Indicated for capillary and parenchymal hemorrhage (trauma, tonsillectomy, during surgery), intestinal bleeding, and thrombocytopenic purpura.|
|DB09244||Pirlindole||For the treatment of major depression.
It is being studied in the treatment of fibromyalgia pain syndrome. One study determined that the effect of pirlindole on sensorimotor performance while driving a motor vehicle shows many similarities to that of placebo. The drug appears to stimulate the central nervous system, rather than exhibit a sedative effect, like many antidepressants. Because of its selective, reversible inhibition of monoamine oxidase (MAO-A) and short half-life, unpleasant "cheese effects" are avoided. This refers to the effects of consuming tyramine-rich foods, such as cheese while medicated with monoamine oxidase inhibitors, leading to severe headaches and hypertension [L1395]. of The available evidence supports pirlindole as a safe and effective treatment option for the management of depression and fibromyalgia syndrome [L1394].
|DB09306||Metralindole||Investigated for the treatment of depression.|
|DB09374||Indocyanine green acid form||For Determining Cardiac Output, Hepatic Function and Liver Blood Flow
For ophthalmic angiography|
|DB11363||Alectinib||Alectinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.|
|DB11577||Indigotindisulfonic Acid||This drug was initially used as a kidney function test. The main application of indigo carmine at this time is localizing and visualizing ureteral orifices during cystoscopy and ureteral catheterization procedures [L2215]. |
|DB11641||Vinflunine||For use as a monotherapy in adults with advanced or transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing therapy [L2381]. |
|DB13783||Acemetacin||Acemetacin is not FDA, Canada or EMA approved, but in the countries where it is marketed it is indicated for the symptomatic treatment of pain and swelling in acute inflammation of the joints in rheumathoid arthritis, osteoarthritis, low back pain and post-surgical pain.[L1045] It is also indicated for the treatment of chronic inflammation of the joints in presence of rheumatoid arthritis, treatment of ankylosing spondylitis, treatment of irritation in the joints and spinal column caused by degenerative disorders, treatment of inflammatory soft-tissue rheumatism syndrome and painful swelling and inflammation caused by injury.[L1044, L1046]|
|DB14627||Oxyphenisatin acetate||Not Available|
|DB07950||Indoleacetic acid||Not Available|
|DB09363||Rauwolfia serpentina root||Rauwolfia alkaloids are indicated in the treatment of hypertension [L1614]. Rauwolfia alkaloids have been used for relief of symptoms in agitated psychotic states such as schizophrenia; however, use as antipsychotics and sedatives have been replaced with the use of more effective, safer agents [L1614].
|DB01430||Almitrine||For the treatment of chronic obstructive pulmonary disease.|